(Q46066974)

19 December 2017

title

The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning (English)

1 reference

19 December 2017

0 references

0 references

1 reference

7

1 reference

19 December 2017

Robin Murray

8

1 reference

19 December 2017

author name string

P D Morrison

1

1 reference

19 December 2017

V Zois

2

1 reference

19 December 2017

D A McKeown

3

1 reference

19 December 2017

T D Lee

4

1 reference

19 December 2017

D W Holt

5

1 reference

19 December 2017

J F Powell

6

1 reference

19 December 2017

language of work or name

English

0 references

publication date

1 April 2009

1 reference

19 December 2017

published in

Psychological Medicine

1 reference

19 December 2017

volume

39

1 reference

19 December 2017

page(s)

1607-1616

1 reference

19 December 2017

issue

10

1 reference

19 December 2017

Pharmacokinetics and pharmacodynamics of cannabinoids

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Cannabis use and outcome of recent onset psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Anomalous experiences and the contents of persecutory delusions during acute psychotic episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Psychiatric Illness in General Practice: A Detailed Study Using a New Method of Case Identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Differential effects of cannabis extracts and pure plant cannabinoids on hippocampal neurones and glia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Psychotic reactions following cannabis use in East Indians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Cannabis and schizophrenia: results of a follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

The cognitive neuroscience of memory function and dysfunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Comorbid substance use and age at onset of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

The cognitive neuroscience of working memory: relevance to CNTRICS and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Pharmacology and effects of cannabis: a brief review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Cannabinoid pharmacology: the first 66 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Causal association between cannabis and psychosis: examination of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Cannabis, the mind and society: the hash realities

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

21 January 2018

Cannabis and the brain

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Cerebellar metabolic activation by delta-9-tetrahydrocannabinol in human brain: A study with positron emission tomography and 18F-2-Fluoro-2-deoxyglucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Endocannabinoid system and stress and anxiety responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Substance misuse at presentation to an early psychosis program

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Is cannabis use psychotogenic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Schizophrenia, ketamine and cannabis: evidence of overlapping memory deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Dichotomous dopaminergic control of striatal synaptic plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Improved and validated method for the determination of Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-THC and 11-nor-9-carboxy-THC in serum, and in human liver microsomal preparations using gas chromatography-mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

Substance use in a population-based clinic sample of people with first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

High-potency marijuana impairs executive function and inhibitory motor control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

7 January 2021

A clinical and metabolic study of acute intoxication with Cannabis sativa and its role in the model psychoses

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

7 January 2021

Chemical basis of hashish activity

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

7 January 2021

Characteristic subjective experiences of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

7 January 2021

Cannabis abuse and the course of recent-onset schizophrenic disorders

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

7 January 2021

Marihuana psychosis. Acute toxic psychosis associated with the use of Cannabis derivatives

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

7 January 2021

The drug abuse screening test

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

7 January 2021

The Michigan Alcoholism Screening Test: The Quest for a New Diagnostic Instrument

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709005522

7 January 2021

10.1017/S0033291709005522

Identifiers

DOI

1 reference

19 December 2017

PubMed ID

19335936

1 reference

19 December 2017